Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.5 EUR
−569.47 M EUR
17.85 M EUR
117.04 M
About Cytokinetics, Incorporated
Sector
Industry
CEO
Robert I. Blum
Website
Headquarters
South San Francisco
Founded
1997
ISIN
US23282W6057
FIGI
BBG01TNXLYV5
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
CYTK5615147
Cytokinetics, Incorporated 3.5% 01-JUL-2027Yield to maturity
—
Maturity date
Jul 1, 2027
CYTK4910847
Cytokinetics, Incorporated 4.0% 15-NOV-2026Yield to maturity
—
Maturity date
Nov 15, 2026
See all 1CYTK bonds
Frequently Asked Questions
The current price of 1CYTK is 51.5 EUR — it has decreased by −1.90% in the past 24 hours. Watch Cytokinetics, Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange Cytokinetics, Incorporated stocks are traded under the ticker 1CYTK.
1CYTK stock has risen by 5.53% compared to the previous week, the month change is a 19.77% rise, over the last year Cytokinetics, Incorporated has showed a 47.14% increase.
We've gathered analysts' opinions on Cytokinetics, Incorporated future price: according to them, 1CYTK price has a max estimate of 102.22 EUR and a min estimate of 34.93 EUR. Watch 1CYTK chart and read a more detailed Cytokinetics, Incorporated stock forecast: see what analysts think of Cytokinetics, Incorporated and suggest that you do with its stocks.
1CYTK reached its all-time high on Oct 9, 2025 with the price of 52.5 EUR, and its all-time low was 26.5 EUR and was reached on May 15, 2025. View more price dynamics on 1CYTK chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1CYTK stock is 1.94% volatile and has beta coefficient of 0.95. Track Cytokinetics, Incorporated stock price on the chart and check out the list of the most volatile stocks — is Cytokinetics, Incorporated there?
Today Cytokinetics, Incorporated has the market capitalization of 6.19 B, it has increased by 10.60% over the last week.
Yes, you can track Cytokinetics, Incorporated financials in yearly and quarterly reports right on TradingView.
Cytokinetics, Incorporated is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
1CYTK earnings for the last quarter are −0.95 EUR per share, whereas the estimation was −1.21 EUR resulting in a 21.66% surprise. The estimated earnings for the next quarter are −1.34 EUR per share. See more details about Cytokinetics, Incorporated earnings.
Cytokinetics, Incorporated revenue for the last quarter amounts to 56.68 M EUR, despite the estimated figure of 1.79 M EUR. In the next quarter, revenue is expected to reach 5.16 M EUR.
1CYTK net income for the last quarter is −114.07 M EUR, while the quarter before that showed −149.17 M EUR of net income which accounts for 23.53% change. Track more Cytokinetics, Incorporated financial stats to get the full picture.
No, 1CYTK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 13, 2025, the company has 498 employees. See our rating of the largest employees — is Cytokinetics, Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cytokinetics, Incorporated EBITDA is −456.37 M EUR, and current EBITDA margin is −2.85 K%. See more stats in Cytokinetics, Incorporated financial statements.
Like other stocks, 1CYTK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cytokinetics, Incorporated stock right from TradingView charts — choose your broker and connect to your account.